Aptamer to il-17 and use thereof

Patent metadata

Field	Value
Publication number	US-2016046944-A1
Application number	US-201414777471-A
Country	US
Kind code	A1
Filing date	Mar 20, 2014
Priority date	Mar 22, 2013
Publication date	Feb 18, 2016
Grant date	—

Abstract

The present invention provides an aptamer that binds to IL-17 to inhibit binding of IL-17 and IL-17 receptor; a complex containing the aptamer and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery medium, drug and the like); a medicament containing the aptamer, or a complex containing the aptamer and a functional substance, a diagnosing drug and labeling agent and the like.

First claim

1 . An aptamer comprising a sequence represented by the following formula (Ia), which binds to IL-17 to inhibit binding of IL-17 and IL-17 receptor:
g(M)g(M)g(M)u(M)a′(M)g′(X1)c(M)c(M)g′g(M)a′(X4)g(X5)g(M)a(M)g(X5)u′(F)c(X7)a′(X2)g(X6)u′(F)r(X3)a′(X3)u(M)c(M)g(M)g(M)u′(X7)a′(M)c′(M)c′(M)c′(M) wherein a, g, c and u are each an RNA wherein the base is adenine, guanine, cytosine and uracil, respectively, r is an RNA wherein the base is adenine or guanine, a′, g′ and c′ are each an RNA or DNA wherein the base is adenine, guanine and cytosine, respectively, u′ is an RNA wherein the base is uracil, a DNA wherein the base is uracil or a DNA wherein the base is thymine, parentheses in nucleotide indicate modification of the nucleotide, (M) indicates that, when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by an O-methyl group, (F) indicates that, when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by a fluorine atom, (X1) indicates that nucleotide is non-modified or phosphorothioated, or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by a fluorine atom, (X2) indicates that nucleotide is non-modified, or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by a fluorine atom, (X3) indicates that nucleotide is non-modified, or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by an O-methyl group, (X4) indicates that nucleotide is non-modified, or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by a fluorine atom or an O-methyl group, (X5) indicates that nucleotide is non-modified or phosphorothioated, (X6) indicates that nucleotide is non-modified or phosphorothioated, or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by an O-methyl group, and (X7) indicates that when nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by a fluorine atom or an O-methyl group.

2 . The aptamer according to claim 1 , comprising a sequence represented by the following formula (Ia′):
g(M)g(M)g(M)u(M)a′(M)g(X5)c(M)c(M)Gg(M)a(X4)gg(M)a(M)g(X5)u′(F)c(X7)a(X2)g(X5)u′(F)r(X3)a(X3)u(M)c(M)g(M)g(M)u(X7)a(M)c′(M)c′(M)c′(M)
wherein a, g, c, u and r, a′, c′ and u′, as well as (M), (F) and (X2)-(X5) and (X7) are as defined for the formula (Ia), and
G is a DNA wherein the base is guanine.

3 . The aptamer according to claim 1 , comprising a sequence represented by the following formula (I):
g(M)g(M)g(M)u(M)a′(M)g′(X1)c(M)c(M)g′g(M)a′(X2)gg(M)a(M)gu′(F)c(F)a′(X2)gu′(F)a(X3)a′(X3)u(M)c(M)g(M)g(M)u′(F)a′(M)c′(M)c′(M)c′(M) wherein a, g, c and u, a′, g′, c′ and u′, as well as (M), (F) and (X1)-(X3) are as defined for the formula (Ia).

4 . The aptamer according to claim 1 , comprising a sequence represented by the following formula (Ia″):
g(M)g(M)g(M)u(M)a′(M)g(X5)c(M)c(M)Gg(M)a(X7)g(X5)g(M)a(M)g(X5)u′(F)c(X7)a(F)g(X6)u′(F)r(X3)a(X3)u(M)c(M)g(M)g(M)u(X7)a′(M)c′(M)c′(M)c′(M)
wherein a, g, c, u and r, a′, c′ and u′, as well as (M), (F), (X3) and (X5)-(X7) are as defined for the formula (Ia), and
G is a DNA wherein the base is guanine.

5 . The aptamer according to claim 4 , wherein, in the formula (Ia″), c′(M)c′(M)c′(M) on the 3′-terminal side is c(M)c(M)c(M).

6 . (canceled)

7 . The aptamer according to claim 1 , comprising the sequence of any of aptamer Nos. 52-94.

8 . The aptamer according to claim 1 , comprising the sequence of any of aptamer Nos. 3-49.

9 . The aptamer according to claim 1 , having a base length of not more than 70.

10 . An aptamer comprising a sequence represented by the following formula (II), which binds to IL-17 to inhibit binding of IL-17 and IL-17 receptor:
g(x1)g(x1)g(x1)u(F)ag(S)c(F)c(F)g′(S)g(x2)aggagu(F)c(F)agu(F)aau(F)c(F)ggu(F)ac′(x3)c′(x3)c′(x3) wherein a, g, c and u are each an RNA wherein the base is adenine, guanine, cytosine and uracil, respectively, g′ and c′ are each an RNA or DNA wherein the base is guanine or cytosine, respectively, parentheses in nucleotide indicate modification of the nucleotide, (F) indicates that a hydroxyl group at the 2′-position of ribose in the nucleotide is substituted by a fluorine atom, (S) indicates that, when nucleotide is an RNA, it is phosphorothioated, (x1) indicates that nucleotide is modified with Locked Nucleic Acid (LNA), or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by an O-methyl group, (x2) indicates that nucleotide is non-modified, or when the nucleotide is an RNA, a hydroxyl group at the 2′-position of ribose therein is substituted by an O-methyl group, and (x3) indicates that nucleotide is non-modified, or modified with LNA.

11 . The aptamer according to claim 10 , comprising the sequence shown by aptamer No. 1 or 2.

12 . The aptamer according to claim 10 , having a base length of not more than 70.

13 . The aptamer according to claim 1 , which is modified with inverted dT or polyethylene glycol.

14 . (canceled)

15 . A complex comprising the aptamer according to claim 1 and a functional substance.

16 . (canceled)

17 . A medicament comprising the aptamer according to claim 1 or a complex comprising the aptamer and a functional substance.

18 . (canceled)

19 . A diagnostic reagent comprising the aptamer according to claim 1 or a complex comprising the aptamer and a functional substance.

20 . A detection probe comprising the aptamer according to claim 1 or a complex comprising the aptamer and a functional substance.

21 . A carrier for IL-17 purification, comprising the aptamer according to claim 1 or a complex comprising the aptamer and a functional substance.

22 . A method of detecting IL-17, comprising using the aptamer according to claim 1 or a complex comprising the aptamer and a functional substance.

23 . A method of purifying IL-17, comprising using the aptamer according to claim 1 or a complex comprising the aptamer and a functional substance.

24 . A method of treating or preventing a disease, comprising administering an effective amount of the aptamer according to claim 1 or a complex comprising the aptamer and a functional substance to a mammal in need thereof.

Assignees

• Univ Tokyo
• Zenyaku Kogyo Kk

Inventors

• Ishiguro Akira
• Nakamura Yoshikazu
• Haruta Kazuhiko
• Otaki Natsuki

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• C12N2310/3521

  Methyl · CPC title

• C07K14/54

  Interleukins [IL] · CPC title

• C12N15/115 Primary

  Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} · CPC title